October 28, 2016 4:27 AM ET


Company Overview of Philogen S.p.A.

Company Overview

Philogen S.p.A. is a biopharmaceutical company that targets cancer and other angiogenesis-associated diseases. It engages in developing immunocytokines, antibodies, and vascular targeting drugs; the discovery, GMP production, and clinical development of immunomodulatory biopharmaceuticals; developing antibody-based therapeutics specific for markers of angiogenesis; and developing DNA-encoded chemical libraries, small molecule drug conjugates, and antibody drug conjugates. It develops DARLEUKIN (L19-IL2), an immunostimulatory compound; TELEUKIN (F16-IL2), a human immunostimulatory antibody; FIBROMUN (L19-TNF), an anti-EDB human antibody; RADRETUMAB (L19-131I), a human vascular targeting antib...

Via Bellaria, 35

Sovicille, SI 53018


Founded in 1996


39 057 717816


39 0577 1781 680

Key Executives for Philogen S.p.A.

Co-Founder, Chief Executive Officer, President and Director
Co-Founder, Director of IP & Licensing and Director
Co-Founder, President of the Scientific Advisory Board and Director
Age: 53
Vice President and Director
Compensation as of Fiscal Year 2016.

Philogen S.p.A. Key Developments

Philogen Enters into Collaboration and Licensing Agreement with Janssen Biotech

Philogen has entered into a collaboration and licensing agreement with Janssen Biotech. The venture will focus on discovering and developing a new class of immunomodulatory therapeutics. Neither company disclosed the terms of the deal.

Philogen S.p.A. Announces Collaboration with Janssen Biotech Inc. to Discover and Develop New Class of Immunomodulatory Therapeutics

Philogen S.p.A. announced that they have entered into a collaboration, option and license agreement with Janssen Biotech Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover and develop a new class of immunomodulatory therapeutics. The agreement was facilitated by Johnson & Johnson Innovation.

Philogen S.p.A. Announces Expanded Research and Development Agreement with AbbVie

Philogen S.p.A. announced that they have entered into a second collaboration with AbbVie to discover and develop novel types of armed antibody products. No financial details of the agreement were released.

Similar Private Companies By Industry

Company Name Region
AdriaCell Srl Europe
AEB SPA Europe
APAvadis Biotechnologies Europe
Arterra Bioscience s.r.l. Europe
Axxam SpA Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Philogen S.p.A., please visit www.philogen.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.